)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Coiled Therapeutics
Coiled Therapeutics (COIL) investor relations material
Coiled Therapeutics H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary5 May, 2026
Executive summary
Completed strategic pivot from pre-clinical to clinical-stage oncology, acquiring exclusive worldwide rights to AO-252, a first-in-class TACC3 inhibitor in Phase I trials.
Raised £8.5 million gross via share placing, supporting clinical milestones through 2026–2027.
Relisted on AIM, changed name to Coiled Therapeutics plc, and restructured Board to align with new clinical focus.
Financial highlights
Reported a consolidated loss of £3,362,074 for 2025, up from £971,803 in 2024, mainly due to impairment charges and AO-252 acquisition costs.
Net equity at year-end was £2,419,645 (2024: £4,889,019); closing cash was £78,054 (2024: £337,112).
Administrative expenses decreased to £683,653 (2024: £931,642); R&D spend was £149,529 (2024: £152,915).
Net cash outflow for 2025 was £259,623; net cash from financing activities was £386,001.
Outlook and guidance
Well-funded to reach key AO-252 clinical milestones, with major data readouts expected in H2 2026.
Plans to initiate dose expansion cohorts in ovarian and prostate cancer, targeting 40 patients by Q3 2026.
Strategic focus remains on AO-252, with STAT-6 siRNA programme under review for potential Phase I trials or out-licensing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Coiled Therapeutics
- Exclusive rights to AO-252 position the company for major oncology breakthroughs and partnerships.COIL
Corporate presentation20 Mar 2026 - Loss narrowed, asset sales agreed, but funding and going concern risks persist.COILH2 202423 Feb 2026
- £30m acquisition delivers clinical-stage assets, AI-driven oncology, and new funding.COILM&A Announcement27 Dec 2025
- Shifted to clinical-stage focus, acquiring Coiled Therapeutics and narrowing net loss.COILH1 20256 Oct 2025
- US$10M Midkine antibody out-licensing, improved loss, and 12 months' funding secured.COILH1 202413 Jun 2025
Next Coiled Therapeutics earnings date
H1 202629 Sep, 2026
Coiled Therapeutics
Next Coiled Therapeutics earnings date
H1 202629 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage